"As manufacturers, payers, and PBMs jockey for position, the patient sits uncomfortably in the middle." CVS Dropping Zepbound: What It Means For Patients, Payers, And Pharma social-www.forbes.com I get my medication from IVIM and they have been great and informative all along the way
Hair follicle signaling
Bigger fish to fry: The surge in GLP-1 adoption adds to the considerable challenges all of these companies already face as economic pressures strain consumers budgets and curb purchase intent
Researchers benchmarking newer incretin candidates frequently include tirzepatide alongside semaglutide for exactly this reason: the delta between them isolates the GIP-R contribution
In the meantime, small and consistent changes can go a long way toward keeping the burn at bay
Ironically, in 1997, the same year Fen Phen & Redux were withdrawn from the market, the FDA Modernization Act (FDAMA) was passed by Congress, a law that further loosened the regulations for DTC marketing, the very thing that directly led to the explosive success of and harm caused by Fen-Phen & Redux